This presentation will focus on the emerging and clinically significant issue of immunotherapy-induced adrenal insufficiency, a growing concern in the era of immune checkpoint inhibitors. As immunotherapy becomes increasingly integral to cancer treatment, particularly in melanoma, the recognition, diagnosis, and long-term management of endocrine adverse effects (immunotherapy induced adrenal insufficiency) is critical to patient safety and outcomes. Presented in collaboration with leading patient advocacy organisations, this session will bring together clinical insight and lived patient experience to highlight current gaps in awareness, challenges in early detection, and opportunities to improve multidisciplinary care pathways. The discussion will emphasise the importance of education for both healthcare professionals and patients, aiming to reduce delayed diagnoses and prevent potentially life-threatening complications. By showcasing the work of the Endocrine Clinical Nurse Specialists, Tania Yarndley and Sarah Fostekew, working alongside Emma Zurwel (Melanoma Australia) and Bronwyn Monro (Australian Addison’s Disease Association Inc.), this presentation demonstrates a collaborative, cross-sector approach that aligns clinical practice with patient advocacy. It underscores our commitment to advancing quality care, improving patient outcomes, and contributing to national and international conversations on immunotherapy safety.